MEDIAN Technologies to take part to the annual 2011 conference of RSNA in Chicago
Presentation of new developments in Oncology Imaging
Participation to presentation sessions about the quantitative Imaging of the future
MEDIAN Technologies Booth 7540, North Building – Hall B
MEDIAN Technologies (ALMDT), services provider for images interpretation and management during oncology clinical trials and software provider for medical imaging, announces its participation to the 97th Annual Meeting of the Radiological Society of North America (RSNA) which will be held from November 27 to December 2, 2011 in Chicago, USA.
On that occasion, MEDIAN Technologies will take part to a series of presentations dedicated to the quantitative imaging and organized under the aegis of the group RSNA/QIBA (Quantitative Imaging Biomarkers Alliance). Sessions of Quantitative Imaging Reading Room of the Future (QIRR) will present to radiologists commercial or under development clinical applications integrating quantitative imaging and imaging biomarkers in the workflow of radiological routine. Sessions regarding MEDIAN Technologies applications will be held to the Lake Side Learning Center Hall E, LL-QRR3011 on:
- Monday, Nov 28 : 12:15 – 1:15 pm
- Tuesday, Nov 29 : 11:45 am – 12:15 pm
- Wednesday, Nov 30 : 12:15 pm -1:15 pm
MEDIAN Lesion Management Solutions (LMS) for CT imaging, as well as new prototypes of clinical applications for other morphological and functional imaging modalities, will be presented to the MEDIAN booth 7540, North Building, Hall B all along the conference.
The annual Meeting of the Radiological Society of North America is the scientific and technical worldwide meeting of the medical imaging professional community. More than 60.000 professionals of the medical imaging will be there.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”